MedPath

Breakthrough in Type 1 Diabetes Treatment with Islet Cell Transplant

Sana Biotechnology reports a significant advancement in Type 1 Diabetes treatment through an allogeneic primary islet cell transplantation without immunosuppression, showcasing promising results in a first-in-human trial.

Sana Biotechnology has made a groundbreaking advancement in the treatment of Type 1 Diabetes (T1D) by successfully performing an allogeneic primary islet cell transplantation on a patient without the need for immunosuppression. This innovative approach utilizes the company's engineered cell product, UP421, which incorporates a novel hypoimmune technology. The results from the first-in-human trial, observed at the 4-week mark, demonstrated not only the survival but also the functional efficacy of pancreatic beta cells. This development represents a significant step forward in the search for effective treatments for T1D, offering hope to patients for a potential cure or long-term management solution without the complications associated with immunosuppressive therapies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Novo Nordisk's Cagrilintide/Semaglutide Combo Shows Superior Weight Loss in Phase III Trial

A fixed-dose combination of cagrilintide and semaglutide led to greater weight loss at 68 weeks compared to either drug alone or placebo in the REDEFINE 1 trial.
The FDA expanded the indication for setmelanotide (Imcivree) to include children as young as 2 years with specific types of genetic obesity.

Gildeuretinol Receives FDA Fast Track and Rare Pediatric Disease Designations for Stargardt Disease

Gildeuretinol (ALK-001) received Rare Pediatric Disease and Fast Track Designations from the FDA for Stargardt disease treatment.
TEASE-1 trial data showed a 21.6% reduction in retinal atrophic lesion growth rate with gildeuretinol compared to the untreated arm.

Radella's MD-18 Shows Promise in Phase Ia Trial for Obesity and Diabetes

Radella Pharmaceuticals' MD-18 demonstrated safety and tolerability in a Phase Ia trial with healthy participants receiving single subcutaneous doses.
The trial showed consistent metabolic improvements seven days post-dose, including reduced leptin levels and enhanced insulin sensitivity.

Tegoprubart Shows Promise in Achieving Insulin Independence After Islet Transplantation

Initial data from a University of Chicago study show that tegoprubart, an anti-CD40L antibody, helped two out of three patients achieve insulin independence after islet transplantation.
Islet engraftment was three to five times higher in patients treated with tegoprubart compared to those receiving standard tacrolimus-based immunosuppression.

Eledon's Tegoprubart Shows Promise in Type 1 Diabetes Islet Transplantation

Eledon Pharmaceuticals' tegoprubart, as part of an immunosuppression regimen, enabled insulin independence in two of three type 1 diabetes subjects after islet transplantation.
Islet engraftment was three to five times higher in subjects treated with tegoprubart compared to those receiving standard tacrolimus-based immunosuppression.

Lantidra Approved for Brittle Type 1 Diabetes, Offering New Hope for Insulin Independence

Lantidra, derived from deceased donor pancreas, is the first FDA-approved therapy for brittle type 1 diabetes, addressing severe low blood sugar episodes.
Clinical trials showed that 70% of Lantidra recipients no longer required insulin one year post-transplant, with over 90% experiencing no hypoglycemia.

Eledon's Tegoprubart Shows Promise in Type 1 Diabetes Islet Transplantation

Eledon Pharmaceuticals reports that tegoprubart, as part of an immunosuppression regimen, enabled insulin independence in two of three type 1 diabetes subjects after islet transplantation.
Islet engraftment was three to five times higher in subjects treated with tegoprubart compared to those receiving standard tacrolimus-based immunosuppression.

Adicet's ADI-001 CAR-T Therapy Expands Clinical Trial to Include Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio's ADI-001, a CAR-engineered gamma delta T-cell therapy, has received FDA clearance to expand its Phase 1 trial to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).
The Phase 1 trial will now include arms for lupus nephritis (LN) and SLE, systemic sclerosis (SSc), antineutrophil cytoplasmic autoantibody associated vasculitis (AAV), and IIM/SPS.

Sernova's Cell Pouch Shows Long-Term Islet Survival in Type 1 Diabetes Trial

Sernova's Cell Pouch demonstrated long-term survival of insulin-producing islet cells after five years in a patient with type 1 diabetes, achieving sustained insulin independence.
Histological data confirmed healthy islet cells producing insulin, glucagon, and somatostatin throughout all chambers of the Cell Pouch, with robust vascularization and no detrimental fibrosis.

FDA Clears IND for Medigene's TCR-T Therapy MDG1015 in Advanced Solid Tumors

Medigene receives FDA clearance for its Investigational New Drug (IND) application for MDG1015, a T-cell receptor engineered T-cell (TCR-T) therapy.
A Phase I clinical trial, EPITOME1015-I, is planned to evaluate MDG1015's safety, feasibility, and preliminary efficacy in patients with advanced solid tumors.

Reference News

[1]
T1D Islet Cell Transplant; 50K Processed Foods Ranked; Obesity and Childhood Cancers
medpagetoday.com · Jan 14, 2025

Sana Biotechnology reported a T1D patient received an allogeneic islet cell transplant without immunosuppression, showin...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy